title: Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1.
authors.forename: Felix
authors.initials: F
authors.lastname: Stickel
authors.forename: Mathias
authors.initials: M
authors.lastname: Worni
authors.forename: Isabelle
authors.initials: I
authors.lastname: Pache
authors.forename: Darius
authors.initials: D
authors.lastname: Moradpour
authors.forename: Beat
authors.initials: B
authors.lastname: Helbling
authors.forename: Jan
authors.initials: J
authors.lastname: Borovicka
authors.forename: Tilman J
authors.initials: TJ
authors.lastname: Gerlach
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000008:administration & dosage* / Q000097:blood*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a